US OptionsDetailed Quotes
FHTX250117P17500
- 0.00
- 0.000.00%
15min DelayClose Dec 23 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover358.98%IV-254.97%PremiumJan 17, 2025Expiry Date12.57Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8184Delta0.0595Gamma0.38Leverage Ratio-0.0232Theta-0.0074Rho-0.31Eff Leverage0.0034Vega
Foghorn Therapeutics Stock Discussion
Sign in to post a comment
$Foghorn Therapeutics (FHTX.US)$ Reuters· 2 mins ago
Foghorn Therapeutics Inc. - Phase 1 Trial of Fhd-286 Showed Clinical Responses but Did Not Meet Threshold
Foghorn Therapeutics Inc. - Phase 1 Trial of Fhd-286 Showed Clinical Responses but Did Not Meet Threshold
3
$Foghorn Therapeutics (FHTX.US)$
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Monday, 16th December at 7:00 am
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone
Company to prioritize investment into proprietary pipe...
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Monday, 16th December at 7:00 am
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone
Company to prioritize investment into proprietary pipe...
$Foghorn Therapeutics (FHTX.US)$ P/L= -25% in 22/23 days
loading...
$Foghorn Therapeutics (FHTX.US)$ testing 🧪🎯📈13$+
loading...
1
3
$Foghorn Therapeutics (FHTX.US)$
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
$Foghorn Therapeutics (FHTX.US)$ Foghorn Therapeutics Inc. is set to share updates on its cancer research pipeline during a conference call and webcast on April 9, 2024, coinciding with the AACR Annual Meeting. The company will outline progress in its preclinical trials, including the development of promising new inhibitors and degraders, with the intention of engaging with investors about these advancements. These forward-looking statements, while offering insights into potential...
1
$Foghorn Therapeutics (FHTX.US)$
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
2
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Foghorn Therapeutics' revenue estimates downgraded by analysts, expected losses per share increased. The company's slower growth compared to industry peers could be a concern for shareholders.
No comment yet
Daily Investors : Hey I started a Bio Tech group, I know your on the same exact thing. If you want in you can. It is only for Bio and Major Pharm. But just what iv put in their over the weekend and today. Def worth it, if you want in send me a FR and I'll add you in
Daily Investors : * Editas Medicine laid off 65% of its workforce after failing to find a partner for its reni-cel program.
* Medtronic's latest PillCam completed its first patient procedure.
* AbbVie acquired oral peptide biotech Nimble for $200 million.
* Novartis paid PTC $1 billi...
Trytosaveabit OP Daily Investors : Thank you! I’ll have to think it over. I’m so busy already that I’m not sure if I’ll be able to contribute much! But again thank you